Carl Zeiss Meditec and Precise Bio, a regenerative medicine company that promotes the use of bioprinted tissues and organs, today announced a partnership to develop and commercialize fabricated corneal tissue for transplantation in patients undergoing endothelial keratoplasty and in need of lenticular surgery natural transplants for keratoconus treatment and vision correction.
Under the terms of the agreement, Carl Zeiss Meditec will invest in Precise Bio and finance the development of Precise Bio’s two corn transplant products and will have exclusive worldwide marketing rights to those products. Financial terms were not disclosed.
“We are very excited about this collaboration, which builds on our ongoing and successful collaboration with ZEISS to develop corneal tissue to address unmet needs in ophthalmology,” said Aryeh Batt, co-founder, and CEO of Precise Bio. “This strategic agreement leverages ZEISS’s global leadership in ophthalmology and the innovative and unique technology of Precise’s 4D biotechnology platform. We are confident that the synergy between the two companies will allow us to develop innovative solutions to restore patients’ vision. , the that brings hope to hundreds of millions of patients around the world”.
Precise Bio combines engineering, biomaterials, cellular technology, bioengineering, and 3D printing into an unprecedented 4D bioproduction platform for transplantable organs and tissues. The company’s proprietary platform technology enables tissue production by “squeezing” cells with unique cellular resolution and spatial precision, enabling complex organoid constructs with structural integrity and long-term cell viability. By overcoming various technological challenges, Precise Bio’s 4D bioproduction technology allows you to reliably scale tissue engineering for clinical use and produce large quantities in a reproducible, quality-controlled, and cost-effective process. Precise Bio’s ophthalmic pipeline consists of three products, two corneal products in collaboration with Carl Zeiss Meditec and a retinal implant for age-related macular degeneration, all of which have shown positive results in animal models. The company’s eye care products serve global markets for more than $10 billion annually.
Bioengineered tissues composed of human cells and natural materials that mimic the anatomical structure and components of natural tissue can replace damaged or diseased tissue, replace donor tissue in case of tissue deficiency, or meet unmet therapeutic needs.